Zhang Jing, Du Xian-Li, Wan Lei, Dong Yan-Ling, Xie Li-Xin
Eye Institute of Shandong First Medical University, Qingdao 266071, Shandong Province, China.
State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Qingdao 266071, Shandong Province, China.
Int J Ophthalmol. 2022 Apr 18;15(4):568-575. doi: 10.18240/ijo.2022.04.07. eCollection 2022.
To evaluate the treatment selections and outcomes of keratoconus and discuss the grading treatment of keratoconus.
Medical records of 1162 patients (1863 eyes) with keratoconus treated with rigid gas permeable (RGP), corneal collagen crosslinking, and keratoplasty were reviewed. The patients were grouped according to the CLEK Study. The advanced group was further divided into a <60 D group and >60 D group. The best-corrected visual acuity (BCVA) and topographic data before and after treatment were recorded.
In the 761 eyes with steep K<52 D, nonsurgical management accounted for 83.4%, while in the 735 eyes with steep K>60 D, surgical management accounted for 90.6%. A total of 618 eyes had improved BCVA at the final follow-up point (>18mo, <0.001). When steep K was <52 D, the BCVA in the RGP group was better than those with lamellar keratoplasty (LKP; =0.028). When steep K was >52 D, the BCVA and topographic astigmatism outcomes showed no differences among the treatment groups. When steep K was >60 D, the BCVA in eyes treated with LKP was worse than those with steep K<60 D (=0.025). The incidence of steep K progression in the RGP group was higher in advanced group (20.0% 10.8%, =0.019). The probability of future keratoplasty in RGP was higher in advanced group (14.8% 7.0%, =0.027). The incidence of steep K progression in the corneal collagen crosslinking (CXL) group was higher in advanced group (32.3% 8.5%, =0.007). Multivariate logistic regression revealed the following related factors for treatment options: steep K [odds ratio (OR)=1.208, 95%CI: 1.052-1.387], TA (OR=1.171, 95%CI: 1.079-1.270), and TCT (OR=0.978, 95%CI: 0.971-0.984). The level of steep K, TA, and TCT all relates to the treatment choices of both keratoplasty and non-keratoplasty, while steep K provided the highest diagnostic accuracy (AUC=0.947, <0.001).
Steep K is an important grading treatment indicator. When steep K is <52 D, RGP lenses should be recommended. It is the best time for LKP when the steep K ranges from 52 to 60 D.
评估圆锥角膜的治疗选择及治疗效果,并探讨圆锥角膜的分级治疗。
回顾了1162例(1863只眼)接受硬性透气性(RGP)角膜接触镜、角膜胶原交联和角膜移植术治疗的圆锥角膜患者的病历。患者根据CLEK研究进行分组。进展期组进一步分为<60 D组和>60 D组。记录治疗前后的最佳矫正视力(BCVA)和地形图数据。
在角膜陡峭度K<52 D的761只眼中,非手术治疗占83.4%;而在角膜陡峭度K>60 D的735只眼中,手术治疗占90.6%。在末次随访时(>18个月,P<0.001),共有618只眼的BCVA得到改善。当角膜陡峭度K<52 D时,RGP组的BCVA优于板层角膜移植术(LKP)组(P=0.028)。当角膜陡峭度K>52 D时,各治疗组的BCVA和地形图散光结果无差异。当角膜陡峭度K >60 D时,接受LKP治疗的眼的BCVA比角膜陡峭度K<60 D的眼差(P=0.025)。RGP组进展期角膜陡峭度进展的发生率高于非进展期组(20.0%对10.8%,P=0.019)。进展期组中RGP术后未来行角膜移植术的概率更高(14.8%对7.0%,P=0.027)。角膜胶原交联(CXL)组进展期角膜陡峭度进展的发生率高于非进展期组(32.3%对8.5%,P=0.007)。多因素logistic回归分析显示治疗选择的相关因素如下:角膜陡峭度K[比值比(OR)=1.208,95%可信区间(CI):1.052 - 1.387]、角膜表面非对称性(TA)(OR=1.171,95%CI:1.079 - 1.270)和中央角膜厚度(TCT)(OR=0.978,95%CI:0.971 - 0.984)。角膜陡峭度K、TA和TCT水平均与角膜移植术和非角膜移植术的治疗选择有关,而角膜陡峭度K的诊断准确性最高(曲线下面积[AUC]=0.947,P<0.001)。
角膜陡峭度K是重要的分级治疗指标。当角膜陡峭度K<52 D时,推荐使用RGP镜片。角膜陡峭度K在52至60 D之间时是行LKP的最佳时机。